Intellectual Property was once again at the heart of news stories across the psychedelic sector this week. At the top of the week, we learned that MagicMed (a company with a primary focus on building a library of IP pertaining to psychedelics) is to be acquired by Nasdaq-listed Enveric Biosciences. However, the announcement was not met with a great deal of fanfare, and Enveric’s stock price…
